Jean‐Claude Barbare

2.7k total citations · 2 hit papers
40 papers, 2.0k citations indexed

About

Jean‐Claude Barbare is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Jean‐Claude Barbare has authored 40 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hepatology, 23 papers in Epidemiology and 9 papers in Oncology. Recurrent topics in Jean‐Claude Barbare's work include Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Liver Disease Diagnosis and Treatment (18 papers) and Cancer Mechanisms and Therapy (5 papers). Jean‐Claude Barbare is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Liver Disease Diagnosis and Treatment (18 papers) and Cancer Mechanisms and Therapy (5 papers). Jean‐Claude Barbare collaborates with scholars based in France, Japan and India. Jean‐Claude Barbare's co-authors include Antoine Galmiche, Bruno Chauffert, Corinne Godin, Christophe Louandre, Zakaria Ezzoukhry, Jean‐Claude Mazière, Chloé Sauzay, Philippe Rougier, Aline Houessinon and Zuzana Saidak and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Radiology.

In The Last Decade

Jean‐Claude Barbare

35 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Iron‐dependent cell death of hepatocellular carcinoma cells exposed to sorafenib

2013 474 citations Christophe Louandre, Zakaria Ezzoukhry et al. International Journal of Cancer profile →
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells

2014 315 citations Christophe Louandre, Ingrid Marcq et al. Cancer Letters profile →

Peers

Countries citing papers authored by Jean‐Claude Barbare

Since Specialization

Citations

This map shows the geographic impact of Jean‐Claude Barbare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Claude Barbare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Claude Barbare more than expected).

Fields of papers citing papers by Jean‐Claude Barbare

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Claude Barbare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Claude Barbare. The network helps show where Jean‐Claude Barbare may publish in the future.

Co-authorship network of co-authors of Jean‐Claude Barbare

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Claude Barbare. A scholar is included among the top collaborators of Jean‐Claude Barbare based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Claude Barbare. Jean‐Claude Barbare is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial 2019 ·Radiology ·Boris Guiu, P. Chevallier, Eric Assénat, Emilie Barbier, Philippe Merle, Antoine Bouvier, Jérôme Dumortier, Éric Nguyen-Khac, Jean Gugenheim, Agnès Rode, Frédéric Oberti, Pierre‐Jean Valette, Thierry Yzet, Olivier Chevallier, Jean‐Claude Barbare, Marianne Latournerie, Mathieu Boulin	27
2	Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C 2019 ·Digestive Diseases and Sciences ·Charlotte Costentin, Philippe Sogni, Bruno Falissard, Jean‐Claude Barbare, Noelle Bendersky, Olivier Farges, Nathalie Goutté	15
3	Parcours de soins du patient atteint de carcinome hépatocellulaire en France : état des lieux en 2017 2017 ·Bulletin du Cancer ·Charlotte Costentin, Nathalie Ganne‐Carrié, Benoı̂t Rousseau, René Gerolami, Jean‐Claude Barbare	1
4	Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib 2015 ·Cancer Letters ·Aline Houessinon, (unknown), (unknown), Christophe Louandre, Rémy Nyga, Corinne Godin, (unknown), (unknown), Zuzana Saidak, Claire Drullion, Jean‐Claude Barbare, Bruno Chauffert, (unknown), Olivier Pluquet, Antoine Galmiche	22
5	New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma 2014 ·Cancer Letters ·Antoine Galmiche, Bruno Chauffert, Jean‐Claude Barbare	74
6	The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells breakdown → 2014 ·Cancer Letters ·Christophe Louandre, Ingrid Marcq, Hicham Bouhlal, Emma Lachaier, Corinne Godin, Zuzana Saidak, Catherine François, Denis Chatelain, Véronique Debuysscher, Jean‐Claude Barbare, Bruno Chauffert, Antoine Galmiche	315
7	EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib 2012 ·International Journal of Cancer ·Zakaria Ezzoukhry, Christophe Louandre, (unknown), Corinne Godin, Bruno Chauffert, Sébastien Dupont, Momar Diouf, Jean‐Claude Barbare, Jean‐Claude Mazière, Antoine Galmiche	148
8	The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma 2012 ·Journal of Hepatology ·Momar Diouf, Thomas Filleron, Jean‐Claude Barbare, (unknown), (unknown), Olivier Bouché, Laëtitia Dahan, Xavier Paolettí, Franck Bonnetain	50
9	BAD, a Proapoptotic Member of the BCL2 Family, Is a Potential Therapeutic Target in Hepatocellular Carcinoma 2010 ·Molecular Cancer Research ·Antoine Galmiche, Zakaria Ezzoukhry, Catherine François, Christophe Louandre, Charles Sabbagh, Éric Nguyen-Khac, Véronique Descamps, (unknown), Corinne Godin, Jean‐Marc Regimbeau, Jean‐Paul Joly, Jean‐Claude Barbare, (unknown), Jean‐Claude Mazière, Denis Chatelain	43
10	Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting 2010 ·Journal of Hepatology ·Caroline Tournoux‐Facon, Xavier Paolettí, Jean‐Claude Barbare, Olivier Bouché, Philippe Rougier, Laëtitia Dahan, Catherine Lombard‐Bohas, Roger Faroux, Jean‐Luc Raoul, Laurent Bedenne, Franck Bonnetain	22
11	Prise en charge thérapeutique du carcinome hépatocellulaire. Où en sommes-nous ? Où allons-nous ? 2009 ·Bulletin du Cancer ·Julien Taı̈eb, Jean‐Claude Barbare, Tarek Boussaha, António Sá Cunha, Thierry de Baère, Olivier Rosmorduc, Jessica Zucman‐Rossi, Dominique Franco	7
12	Dépistage et traitement précoce du carcinome hépatocellulaire 2008 ·Gastroentérologie Clinique et Biologique ·Nathalie Ganne‐Carrié, Sylvie Chevret, Jean‐Claude Barbare, (unknown), Véronique Grando, (unknown), Michel Beaugrand, Jean–Claude Trinchet	0
13	Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials 2008 ·Annals of Oncology ·Sandra Collette, Franck Bonnetain, Xavier Paolettí, Michel Doffoël, Olivier Bouché, Jean‐Luc Raoul, Philippe Rougier, F. Masskouri, Laurent Bedenne, Jean‐Claude Barbare	64
14	Management practices for gastrointestinal hemorrhage related to portal hypertention in cirrhotic patients: evaluation of the impact of the Paris consensus workshop 2007 ·Gastroentérologie Clinique et Biologique ·(unknown), Frédéric Oberti, Pierre Bernard, Éric Bartoli, (unknown), P Renard, Jean–François Cadranel, Brigitte Bernard‐Chabert, Jean‐Claude Barbare, Isabelle Ingrand, (unknown), Michel Beauchant, (unknown), (unknown)	6
15	Medical treatments for hepatocellular carcinoma (HCC): what’s next? 2006 ·Annals of Oncology ·Julien Taı̈eb, Jean‐Claude Barbare, Philippe Rougier	25
16	Colite aiguë apparue dans les jours suivant le début d’un traitement par célécoxib 2005 ·Gastroentérologie Clinique et Biologique ·(unknown), Audrey Imbert, (unknown), (unknown), Jean‐Claude Barbare, Jean‐Paul Latrive, M Biour	2
17	Hepatitis C virus infection risk factors in patients admitted in hospital emergency departments in Picardy. Value of oriented screening based on recommendations of the 'Direction Générate de la Santé 1999 ·European Journal of Gastroenterology & Hepatology ·Dominique Capron, (unknown), (unknown), Jean‐Claude Barbare, (unknown), Abdeslam Bental, Jean–François Cadranel, (unknown), Philippe Lévy, (unknown), (unknown), (unknown), (unknown), (unknown), Marc Bernard, (unknown), (unknown)	9
18	Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: A multicenter sequential trial 1992 ·Hepatology ·Jean–Claude Trinchet, Beverley Balkau, Renée E. Poupon, (unknown), P Callard, C Gotheil, Jean‐Didier Grangé, Denis Vetter, Arnaud Pauwels, H Labadie, Olivier Chazouillères, Philippe Mavier, Hervé Desmorat, Jean‐Pierre Zarski, Jean‐Claude Barbare, (unknown), Alexandre Pariente, Dominique Roulot, Michel Beaugrand	52
19	Intrinsic hepatic clearance and child-turcotte classification for assessment of liver function in cirrhosis 1985 ·Journal of Hepatology ·Jean‐Claude Barbare, R.E. Poupon, Patrice Jaillon, (unknown), F Darnis, Raoul Poupon	40
20	Fasting serum bile acid level in cirrhosis 1985 ·Journal of Hepatology ·Shamsul Islam, R. Poupon, Jean‐Claude Barbare, Yves Chrétien, F Darnis	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact